Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.28 USD | -0.56% | 0.00% | +40.43% |
Apr. 15 | CorMedix's DefenCath Now Commercially Available For US Inpatient Use | MT |
Apr. 15 | CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin) | CI |
Financials (USD)
Sales 2024 * | 25.16M | Sales 2025 * | 81.93M | Capitalization | 290M |
---|---|---|---|---|---|
Net income 2024 * | -45M | Net income 2025 * | 6M | EV / Sales 2024 * | 14.2 x |
Net Debt 2024 * | 67.4M | Net Debt 2025 * | 48.88M | EV / Sales 2025 * | 4.14 x |
P/E ratio 2024 * |
-7.14
x | P/E ratio 2025 * |
-55.6
x | Employees | 83 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.99% |
Latest transcript on CorMedix Inc.
1 day | -0.56% | ||
Current month | +24.53% | ||
1 month | +24.53% | ||
3 months | +57.61% | ||
6 months | +76.00% | ||
Current year | +40.43% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Todisco
CEO | Chief Executive Officer | 48 | 22-03-17 |
Mathew David
DFI | Director of Finance/CFO | 47 | 20-05-10 |
Tushar Mukherjee
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Myron Kaplan
CHM | Chairman | 79 | 16-04-26 |
Steven Lefkowitz
DFI | Director of Finance/CFO | 68 | 11-08-14 |
Alan Dunton
BRD | Director/Board Member | 70 | 19-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +2.43% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 5.28 | -0.56% | 365,723 |
24-04-26 | 5.31 | +2.31% | 315,424 |
24-04-25 | 5.19 | -2.63% | 745,281 |
24-04-24 | 5.33 | -2.20% | 422,944 |
24-04-23 | 5.45 | +3.22% | 572,806 |
Delayed Quote Nasdaq, April 29, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.43% | 290M | |
+4.06% | 69.85B | |
+11.77% | 8.98B | |
-14.44% | 4.89B | |
+41.60% | 4.44B | |
+5.96% | 3.95B | |
+23.46% | 2.49B | |
-19.32% | 2.4B | |
-27.04% | 2.28B | |
+7.97% | 1.96B |
- Stock Market
- Equities
- CRMD Stock